GlassScriptPhysician profile
Dipen V Shah
NPI 1093804874
$8,012.45
in general payments reported to CMS, 2019-2025
54 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $547 · 2021: $1,383 · 2022: $525 · 2023: $1,012 · 2024: $1,198 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.36 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $840.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $664.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $656.95 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $643.99 | 2019-2025 | |
| Abbvie INC. | $604.39 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Amgen INC. | $451.91 | 2019-2025 | Evenity, Repatha, Otezla |
| Sentiar, INC. | $400.00 | 2025 | Commandep |
| Pfizer INC. | $313.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $269.99 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $265.91 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $190.16 | 2019-2021 | |
| Abbott Laboratories | $165.06 | 2021-2024 | Freestyle Libre 3, Tacticath Ablation Catheter, Sensor Enabled |
| Antares Pharma, INC. | $148.88 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $147.41 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $124.67 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipen Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.